- Hauser.chem - maillist.au.dk

Hauser GM
by Nicole Maria Hauser 21 Oct '25

21 Oct '25

1 0

Organic Synthesis&Biocatalysis GM
by Nicole Maria Hauser 21 Oct '25

21 Oct '25

Dear all, This meeting will take place in 1171-230 (I will confirm once it draws closer). Best, Nicole

1 0

Organic Synthesis&Biocatalysis GM
by Nicole Maria Hauser 21 Oct '25

21 Oct '25

1 0

Organic Synthesis&Biocatalysis GM
by Nicole Maria Hauser 21 Oct '25

21 Oct '25

1 0

Organic Synthesis&Biocatalysis GM
by Nicole Maria Hauser 21 Oct '25

21 Oct '25

1 0

Organic Synthesis&Biocatalysis GM
by Nicole Maria Hauser 21 Oct '25

21 Oct '25

1 0

Organic Synthesis&Biocatalysis GM
by Nicole Maria Hauser 21 Oct '25

21 Oct '25

1 0

Organic Synthesis&Biocatalysis GM
by Nicole Maria Hauser 21 Oct '25

21 Oct '25

1 0

Organic Synthesis and Biocatalysis
by Nicole Maria Hauser 21 Oct '25

21 Oct '25

Dear Group, I am trying to schedule individual meetings now because of changing locations. Best, Nicole

1 0

[org.chem] Lecture by Matthias Gehringer Thursday 23-10-2025
by Vibeke Henriette Lauridsen 20 Oct '25

20 Oct '25

Speaker: Prof. Matthias Gehringer, University of Tübingen, Germany Time-Place: Thursday 23/10-2025 10.15 in 1511-312 (krydsfeltet) Title: Covalent Protein Kinase Inhibitors: Exploring Understudied Targets and Unconventional Binding Modes Abstract: Protein kinases have been pursued as drug targets for more than 20 years, but a significant part of the human "kinome" has not yet been addressed with specific inhibitors, despite its likely medical relevance. Our research group focuses on the identification of new covalent inhibitors for both validated and understudied protein kinases. Through our recent work, we and our collaborators have employed rational design approaches as well as intact-protein mass spectrometry (MS) screens to explore kinase-inhibitor-like covalent libraries equipped with cysteine and tyrosine/lysine reactive "warheads". These efforts have yielded a variety of promising hits. In addition to mass spectrometry, we utilized a suite of complementary methods, including thermal shift assays, biochemical enzyme assays, cellular assays, and X-ray crystallography, for further investigation and thorough validation. My presentation will detail our progress in extending the range of known protein kinase inhibitors, especially focusing on new inhibitors of lesser-studied kinases. Additionally, I will discuss non-conventional binding modes we have identified, which provide a basis for ongoing medicinal chemistry optimization. These results help to unlock a broader range of kinase targets and support current and future efforts in kinase inhibitor development. _______________________________________________ org.chem mailing list -- org.chem(a)maillist.au.dk

2 1